Genomic Health Announces Expansion of Oncotype DX(R) Breast Cancer Test to Include Quantitative Estrogen Receptor (ER) and Progesterone Receptor (...(e reimbursement for Oncotype DX through ...)

Date:6/2/2008

e reimbursement for Oncotype DX through contracts, agreements and policy decisions. Both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched its first test, Oncotype DX(R), which has been shown to predict the likelihood chemotherapy benefit as well as recurrence in early-stage breast cancer patients. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the company's belief that the quantitative measurement of individual tumor biology is the methodology of the future and the belief that providing quantitative ER and PR scores enhances the value of Oncotype DX. These risks and uncertainties include, but are not limited to: the results of additional clinical studies; the risk that we may not obtain sufficient levels of reimbursement for any future tests we may develop; our ability to develop and commercial
'/>"/>

SOURCE Genomic Health, Inc. Copyright©2008 PR Newswire. All rights reserved

3 GOOD

Page: 1 2 3 4
Related biology technology :

1. Ipsogen Launches MapQuant Dx(TM) Genomic Grade Test to Identify Breast Cancer Patients who Benefit From Chemotherapy
2. New insights into cellular reprogramming revealed by genomic analysis
3. /C O R R E C T I O N -- Rosetta Genomics Ltd/
4. Rosetta Genomics Reports First Quarter 2008 Financial Results
5. Rosetta Genomics Announces Conference Call and Webcast of First Quarter Financial Results
6. Albert Einstein College of Medicine Receives $25-Million Gift to Support Stem Cell and Epigenomic Research and Clinical Skills Training
7. Genomic Health Announces First Quarter 2008 Financial Results and Business Progress
8. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
9. NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008
10. Genomic Health to Announce First Quarter 2008 Financial Results and Host Conference Call on Tuesday, May 6, 2008
11. Rosetta Genomics Announces Expansion of its MicroRNA Intellectual Property Estate